The effect of empagliflozin (sodium–glucose cotransporter-2 inhibitor) on osteoporosis and glycemic parameters in patients with type 2 diabetes: a quasi-experimental study
Empagliflozin, when combined with symptomatic treatment, demonstrates a positive clinical effect in patients with diabetic osteoporosis. The treatment effectively improves blood glucose metabolism, bone mineral density, and phosphorus and calcium metabolism, ultimately leading to a significant reduction in the incidence of fracture.
Authors
- Ke‐Qin Zhang (ORCID: https://orcid.org/0000-0002-7615-6509)
- Yanli Jiang
- Aili Guo (ORCID: https://orcid.org/0000-0002-1061-5135)
- Huaning Liu
- Jinmei Tan
Institutions
- Tongji University (CN)
- Shanghai Ship and Shipping Research Institute (CN)
- Yangtze Optical Electronic (China) (CN)
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- BMC Musculoskeletal Disorders
- Published
- 2024-10-07
- DOI
- https://doi.org/10.1186/s12891-024-07900-5
- Citations
- 4
- Primary Topic
- Metabolism, Diabetes, and Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.94